What to watch when Lilly reports Q3 results on 29 October
Ahead of Lilly's 29 October results, the piece notes Q2 Mounjaro sales rose 91% to $9.94bn and Zepbound 46% to $4.93bn, with 2026 revenue guidance already raised to $85bn to $87bn. Watch points include a possible third guidance raise, Novo's pricing moves and the retatrutide filing, which Lilly's CEO says awaits manufacturing work.
Source: 24/7 Wall St. (25 Oct 2026).